N2007-01: Ultratrace™ Iobenguane I 131 in Patients With Relapsed/Refractory High-Risk Neuroblastoma
Completed
Molecular Insight Pharmaceuticals, Inc.
Phase 2
2008-06-01
RATIONALE: Radioactive drugs, such as iodine I 131 metaiodobenzylguanidine (MIBG), may carry
radiation directly to tumor cells and not harm normal cells. A bone marrow or peripheral stem
cell transplant using stem cells from the patient may be able to replace blood-forming cells
that were destroyed by I 131 MIBG.
PURPOSE: This phase II trial is studying the side effects and best dose of iodine I 131 MIBG
followed by a stem cell transplant in treating young patients with relapsed or refractory
high-risk neuroblastoma.
Expanded Access Program of Ultratrace Iobenguane I131 for Malignant Relapsed/Refractory Pheochromocytoma/Paraganglioma
Approved for marketing
Molecular Insight Pharmaceuticals, Inc.
1969-12-31
The purpose of this sub-study is to provide expanded access of AZEDRA (Ultratrace Iobenguane
I 131) and to evaluate the safety and tolerability of AZEDRA in subjects with iobenguane-avid
malignant and/or recurrent pheochromocytoma/paraganglioma (PPGL).
A Clinical Trial Evaluating the Safety of Combining Lutathera(R) and Azedra(R) to Treat Mid-gut Neuroendocrine Tumors
Not yet recruiting
National Cancer Institute (NCI)
Phase 1/Phase 2
2021-11-01
This study is designed to identify the best tolerated doses of Lutathera® and Azedra® when
co-administered to treat midgut neuroendocrine tumors. These drugs are radioactive drugs,
known as radionuclide therapy, and are both approved in the treatment of midgut
neuroendocrine tumor as single agents (not together). Currently, the safest and best
tolerated doses of these drugs (when combined) is unknown. That is the purpose of this
clinical trial.
A Clinical Trial Evaluating the Safety of Combining Lutathera(R) and Azedra(R) to Treat Mid-gut Neuroendocrine Tumors
Not yet recruiting
National Institutes of Health (NIH)
Phase 1/Phase 2
2021-11-01
This study is designed to identify the best tolerated doses of Lutathera® and Azedra® when
co-administered to treat midgut neuroendocrine tumors. These drugs are radioactive drugs,
known as radionuclide therapy, and are both approved in the treatment of midgut
neuroendocrine tumor as single agents (not together). Currently, the safest and best
tolerated doses of these drugs (when combined) is unknown. That is the purpose of this
clinical trial.
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors.
Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data.
The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free.
We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models.
By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice.
thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user.
Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
Alerts Available With Subscription
Alerts are available for users with active subscriptions.
